Clinical Trial Update: Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial update on certolizumab for Crohn's disease evaluating corticosteroid-sparing effect; terminated with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Certolizumab (certolizumab)

Snippet

Sponsor: UCB Pharma | Conditions: Crohn's Disease | Phase 3 | Status: TERMINATED | Results posted: 2010-12-01